This cross-sectional study reveals the seroprevalence of hepatitis B, hepatitis C and HIV in multi-transfused thalassemia major patients. Thirty-four out of 79 (43.0%) patients enrolled in the study serologically tested positive for hepatitis C (mean ± standard deviation age = 12 ± 4.1 years), four (5.1%) for hepatitis B and none for HIV. Some of the measures that should be adapted are: safe blood transfusions; awareness programmes through print and electronic media; and the early screening of such hazardous infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1258/td.2010.100158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Barriers and facilitators of integrated hepatitis B, C, and HIV screening among pregnant mothers and newborns attending maternal and newborn clinics in Koboko District, Uganda: a qualitative inquiry of providers' perspective.
BMC Infect Dis
January 2025
Department of Family Medicine, Epidemiology & Community Health, School of Health Sciences, Kenyatta University, Nairobi, Kenya.
Background: HIV and HBV remain significant public health challenges characterized by high prevalence, morbidity, and mortality, especially among women of reproductive age in Uganda. Patients with HBV do not receive routine counselling and education, and there are limited resources for laboratory investigation coupled with a high loss to follow-up. This study set out to assess barriers and facilitators of integrated viral hepatitis B C and HIV care model to optimize screening uptake among mothers and newborns at health facilities in Koboko District, west Nile sub-region, Uganda.
View Article and Find Full Text PDFIdentification of risk factors for suboptimal adherence in people living with HIV through measurement of medication possession ratio: a cross-sectional study.
AIDS Care
January 2025
Department of Knowledge Management, Sociedad Integral de Especialistas en Salud (SIES Salud IPS), Bogotá, Colombia.
The most significant progress in addressing the HIV/AIDS epidemic has been the development of antiretroviral therapy (ART). However, ensuring a high degree of treatment adherence is necessary to prevent resistance and disease progression. We conducted a cross-sectional study to evaluate adherence to ART through the calculation of the medication possession ratio (MPR) and to identify risk factors for suboptimal adherence in a cohort of HIV-positive patients receiving care at a Colombian healthcare institution across 16 cities.
View Article and Find Full Text PDFLiver Enzyme Elevation After Hepatitis C Virus Cure: Is There a Sex Effect? (ANRS CO13 HEPAVIH Cohort).
J Viral Hepat
March 2025
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
Sero-prevalence of hepatitis B and C and HIV among students at the Federal University of Health Sciences, Azare.
Niger Med J
January 2025
Department of Obstetrics and Gynaecology, Federal University of Health Sciences, Azare, Bauchi State, Nigeria.
Background: Infection with the human immunodeficiency virus and hepatitis viruses B and C have been reported to be endemic in some Nigeria's institutions of higher learning. Several studies have reported varying prevalence rates for hepatitis B and C viruses and HIV among undergraduate students in Nigerian universities.
Methodology: A cross-sectional descriptive prevalence study of hepatitis B and C viruses and HIV among students at Federal University of Health Sciences, Azare conducted on the 2nd of December 2023.
Mindray CL-900i assay: An effective assay for hepatitis B surface antigen screening with superior specificity.
IJID Reg
March 2025
Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Objectives: The chemiluminescence immunoassay automated Abbott ARCHITECT hepatitis B surface antigen (HBsAg) screening assay is globally recognized for its superior sensitivity but notably low specificity. This mandates positive results confirmation by another confirmatory assay, such as the widely used Abbott ARCHITECT HBsAg neutralizing assay. This study aimed to evaluate the performance of the new chemiluminescence immunoassay, Mindray CL-900i HBsAg screening assay in comparison to the ARCHITECT neutralizing/confirmatory assay.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!